An Open-label Study to Evaluate the Long-term Safety, Tolerability and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2019
Price : $35 *
At a glance
- Drugs Mavoglurant (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 08 Feb 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database record.
- 11 Apr 2016 Status changed from completed to discontinued because study treatment AFQ056 failed to demonstrate efficacy in the adult patient with Fragile X Syndrome in 2 other clinical studies (CAFQ056B2214 and CAFQ056A2212
- 12 Feb 2015 Status changed from discontinued to completed, as reported by ClinicalTrials.gov.